cbdMD, INC.
|
(Exact name of registrant as specified in its charter)
|
North Carolina
|
001-38299
|
47-3414576
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
_______________________________________
|
(Former name or former address, if changed since last report)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
common
|
YCBD
|
NYSE American
|
8% Series A Cumulative Convertible Preferred Stock
|
YCBD PR A
|
NYSE American
|
Emerging growth company ☐
|
Item 7.01
|
Regulation FD Disclosure.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Incorporated by Reference
|
Filed or
|
|||||||||
No.
|
Exhibit Description
|
Form
|
Date
Filed
|
Number
|
Furnished
Herewith
|
|||||
99.1
|
Furnished
|
|||||||||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
cbdMD, Inc.
|
||
Date: February 29, 2024
|
By:
|
/s/ T. Ronan Kennedy
|
T. Ronan Kennedy, Interim Chief Executive Officer and Chief Financial Officer
|
Exhibit 99.1